HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases.

AbstractOBJECTIVE:
The objective of this study is to analyze the expression and clinical role of integrin-linked kinase (ILK), α-parvin, β-parvin and migfilin in advanced-stage serous ovarian carcinoma.
METHODS:
Expression of these 4 proteins was investigated in 205 effusions and in 94 patient-matched solid lesions (33 primary tumors and 61 solid metastases) using immunohistochemistry. Protein expression was analyzed for association with clinicopathologic parameters and survival.
RESULTS:
ILK, α-parvin, β-parvin and migfilin were expressed in tumor cells in 53%, 2%, 28% and 53% of effusions and 57%, 20%, 83% and 25% of solid lesions, respectively. Statistical analysis showed significantly higher α-parvin and β-parvin expression in primary carcinomas (p=0.02 and p=0.001, respectively) and solid metastases (p=0.001 and p<0.001, respectively), compared to effusions, with opposite findings for migfilin (p=0.006 and p=0.008 for primary carcinomas and solid metastases, respectively). ILK expression was comparable at all anatomic sites. β-Parvin expression in effusions was associated with better response to chemotherapy at diagnosis (p=0.014), with no other significant association with clinicopathologic parameters or survival. Expression in primary tumors and solid metastases was similarly unrelated to clinicopathologic parameters or survival.
CONCLUSIONS:
This study provides further evidence to our previous observations that the adhesion profile of ovarian serous carcinoma cells in effusions differs from their counterparts in primary carcinomas and solid metastases. β-Parvin may be a novel marker of chemoresponse in metastatic ovarian carcinoma.
AuthorsBen Davidson, Arild Holth, Mai T P Nguyen, Claes G Tropé, Chuanyue Wu
JournalGynecologic oncology (Gynecol Oncol) Vol. 128 Issue 2 Pg. 364-70 (Feb 2013) ISSN: 1095-6859 [Electronic] United States
PMID23099104 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
Chemical References
  • Cell Adhesion Molecules
  • Cytoskeletal Proteins
  • FBLIM1 protein, human
  • Microfilament Proteins
  • PARVA protein, human
  • PARVB protein, human
  • Actinin
Topics
  • Actinin (biosynthesis)
  • Adult
  • Aged
  • Aged, 80 and over
  • Ascitic Fluid (metabolism, pathology)
  • Cell Adhesion Molecules (biosynthesis)
  • Cystadenocarcinoma, Serous (metabolism, pathology)
  • Cytoskeletal Proteins (biosynthesis)
  • Female
  • Humans
  • Immunohistochemistry
  • Microfilament Proteins (biosynthesis)
  • Middle Aged
  • Neoplasm Metastasis
  • Ovarian Neoplasms (metabolism, pathology)
  • Tissue Array Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: